RS
CRSP icon

Rakuten Securities’s CRISPR Therapeutics CRSP Stock Holding History

Rakuten Securities’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.9K Sell
731
-13
-2% -$685 0.01% 291
2026
Q1 		$35.4K Sell
744
-435
-37% -$22.9K 0.01% 284
2025
Q4 		$61.8K Buy
1,179
+811
+220% +$48.6K 0.02% 223
2025
Q3 		$23.9K Buy
368
+282
+328% +$16.2K 0.01% 305
2025
Q2 		$4.18K Sell
86
-9
-9% -$348 ﹤0.01% 511
2025
Q1 		$3.23K Sell
95
-25
-21% -$1.06K ﹤0.01% 539
2024
Q4 		$4.72K Sell
120
-239
-67% -$11.3K ﹤0.01% 485
2024
Q3 		$16.9K Buy
359
+168
+88% +$8.52K 0.01% 286
2024
Q2 		$10.3K Sell
191
-26
-12% -$1.5K ﹤0.01% 325
2024
Q1 		$14.8K Buy
+217
New +$15.5K 0.01% 285

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Rakuten Securities's CRSP Position: Q2 2026 in Review

Rakuten Securities reduced its CRISPR Therapeutics (CRSP) stake by 1.7% in Q2 2026, selling an estimated $685 and leaving 731 shares worth $39.9K. The position accounts for 0.01% of the portfolio, ranked #291.

Rakuten Securities first reported a position in CRSP in Q1 2024 and has held it in 10 quarters since. The position peaked at $61.8K in Q4 2025. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Rakuten Securities held 731 shares of CRISPR Therapeutics worth $39.9K as of Q2 2026.
  • Rakuten Securities sold 13 CRISPR Therapeutics shares in Q2 2026, an estimated $685.
  • CRISPR Therapeutics made up 0.01% of Rakuten Securities's portfolio in Q2 2026, its #291 holding.
  • Rakuten Securities first reported a position in CRISPR Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Rakuten Securities's CRISPR Therapeutics position peaked at $61.8K in Q4 2025.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Rakuten Securities's 13F filing for Q2 2026, filed 12 Aug 2026.